News
Capricor Therapeutics is expected to release data from the phase 3 HOPE-3 trial in Q3'25, thus presenting a potential path ...
The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...
Capricor Therapeutics (CAPR) shares fell Friday after the company announced it received a complete response letter from the FDA for its Biologics License Application for Deramiocel.
The U.S. Food and Drug Administration has published more than 200 complete response letters, or decision letters, sent as ...
As the controversial powerline fight continues, the developers have begun sending out letters to residents about surveys starting, however the letter raises mor ...
The U.S. Food and Drug Administration on Thursday publicly shared over 200 archived so-called complete response letters related to medicines that were later approved, in a bid to improve transparency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results